Trelegy▼Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Product menu

Trelegy Ellipta Price UK hero
Trelegy Ellipta Price

A lower cost (at £44.50) than commonly prescribed multiple inhaler triple therapies.1,2

At £44.50 Trelegy Ellipta costs less than commonly prescribed multiple inhaler triple therapies in the UK1,2

Cost of Trelegy Ellipta compared to other branded multiple inhaler triple therapy combinations in COPD:

Graph showing price of COPD triple therapy options in UK

*Spiriva HandiHaler; NB: All doses stated are delivered doses. Other triple therapy options are available. BUD, budesonide; FOR, formoterol; FP, fluticasone propionate; mcg, microgram; MITT, multiple inhaler triple therapies; SAL, salmeterol; SITT, single inhaler triple therapy TIO, tiotropium; FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol

SERETIDE (Salmeterol xinafoate/fluticasone propionate) Prescribing Information

Get started with Trelegy Ellipta

Order demo device

PATIENT RESOURCES

Carbon footprint of COPD inhalers

Reducing carbon impact of inhalers

Find out about the carbon impact of different inhaler types and more about the Ellipta device on our device & dosing page.

LEARN MORE
Ellipta inhaler device demonstration

Easy-to-use Ellipta device³⁻⁵

Trelegy is delivered in the easy-to-use Ellipta device3-5. See how it compares to other commonly prescribed inhaler devices.

LEARN MORE
NICE guidelines for COPD

NICE Guidelines on COPD

What does NICE say about the appropriate time to prescribe triple therapy? 
 

LEARN MORE
Trelegy Ellipta quick links

Dosing & Device

See Trelegy dosing information

Molecules

Learn about fluticasone furoate, umeclidinium and vilanterol

Trelegy Ellipta home

Once-daily triple therapy inhaler for COPD⁶

Identifying patients

Prescribing COPD triple therapy

Footnotes

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β₂-agonist or a combination of a long-acting β₂-agonist and a long-acting muscarinic antagonist.6

Trelegy Ellipta is generally well tolerated. Common adverse reactions include: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis, arthralgia, sinusitis, oropharyngeal pain, bronchitis, constipation, candidiasis of mouth and throat, urinary tract infection.6 This is not an exhaustive list. Please consult the Summary of Product Characteristics for a full list of adverse reactions before prescribing.

In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta.6

References

  1. MIMS Available at: https://www.mims.co.uk/. (Accessed Jan 2020)
  2. GSK Data on file: Combined Triple Therapy Combinations for COPD UK/TLY/0089/18 (REF-3515)
  3. Svedsater H et al BMC Pulm Med 2013; 13:1–14.
  4. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  5. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873–1880.
  6. Trelegy Ellipta SmPC

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with

PM-GB-FVU-WCNT-200006 | February 2021